Compare DraftKings Inc (DKNG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Novartis AG — how do they compare? DraftKings Inc trades at $25.33 (market cap $12.05B), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG is far larger — about 24.7× DraftKings Inc's market cap, and Novartis AG pays a 3.02% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals.
| DKNG | NVS | |
|---|---|---|
Market Cap | $12.05B | $298.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $48.23 | $168.62 |
52-Week Low | $20.72 | $119.31 |
Enterprise Value | $12.98B | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $24.03, up 8.39% today, but remains under pressure with a bearish technical signal. Recent Q2 2026 earnings missed expectations, with an EPS loss of $0.14 versus a $0.02 profit forecast. Revenue grew to $6.05 billion in 2025, but net income margins are negative. Analyst consensus is bullish with a $33.86 price target, though news highlights competition from prediction markets and promotional costs.
The outlook is mixed: strong revenue growth and positive operating cash flow support long-term potential, but profitability challenges and competitive threats pose risks. Upside depends on execution in new markets and cost management, while investor sentiment is cautious amid recent earnings misses and bearish technical trends.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
